Vivani Medical (VANI) EBITDA (2014 - 2026)

Vivani Medical has reported EBITDA for 13 years, with the latest figure at -$6.9 million in Q2 2026.

• On a quarterly basis, EBITDA rose 7.88% year-over-year to -$6.9 million in Q2 2026; TTM through Jun 2026 was -$27.2 million, a 1.64% decrease from a year earlier, with the FY2025 full-year figure at -$27.6 million, down 11.67% from the prior year.
• EBITDA was -$6.9 million for Q2 2026 at Vivani Medical, down from -$6.8 million in the prior quarter.
• The five-year high for EBITDA was -$3.9 million in Q1 2022, with the low at -$7.8 million in Q4 2022.
• Average EBITDA over 5 years is -$6.3 million, with a median of -$6.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA slumped 503.41% in 2022, then advanced 20.19% in 2023.
• Over 5 years, EBITDA stood at -$7.8 million in 2022, then increased by 20.19% to -$6.2 million in 2023, then retreated by 3.91% to -$6.5 million in 2024, then fell by 5.42% to -$6.8 million in 2025, then declined by 0.94% to -$6.9 million in 2026.
• The last three EBITDA figures came in at -$6.9 million (Q2 2026), -$6.8 million (Q1 2026), and -$6.8 million (Q4 2025), per Business Quant data.